Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tissue Repair Cell Therapy (TRC) is an autologous cell therapy developed by Aastrom Biosciences, Inc. It involves the collection and processing of a patient's own bone marrow to expand specific cell populations, including early stem cells and CD90+ mesenchymal stem cells. These cells are then transplanted to the site of injury to promote tissue regeneration. The therapy has been investigated for its potential to regenerate bone in alveolar bone defects, treat non-union fractures, and induce revascularization in diabetic patients suffering from critical limb ischemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tissue Repair Cell Therapy.